GlassScriptPhysician profile
Mary P Forkin
NPI 1811072705
$10,823.18
in general payments reported to CMS, 2019-2025
44 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $1,648 · 2021: $1,432 · 2022: $2,199 · 2023: $1,680 · 2024: $1,421 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,144.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,694.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $965.14 | 2021-2025 | |
| Lilly USA, LLC | $881.11 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $820.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.23 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $323.15 | 2020-2024 | Nexletol |
| Amgen INC. | $323.10 | 2019-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $310.17 | 2019-2024 | |
| Glaxosmithkline, LLC. | $295.12 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $282.97 | 2019-2025 | Veozah |
| Pfizer INC. | $207.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $190.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $188.72 | 2019-2023 | Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $186.51 | 2019-2023 | Livalo, Seglentis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Forkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.